icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2015
50th Annual Meeting of the European
Association for the Study of the Liver
Vienna, Austria  April 22-26
Back grey_arrow_rt.gif
 
 
 
A Phase 1 Study to Evaluate the Interaction of HCV NS5B Inhibitor MK-3682 With HCV NS3/4A Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8408 in Healthy Subjects
 
 
  Reported by Jules Levin
EASL 2015 Apr 22-26 Vienna, Austria
 
Xiao-Jian Zhou1; Eric Sicard2; Jie Chen1; Dodie Frank1; Wei Gao3; Matthew L. Rizk3; Elizabeth G. Rhee3; Joan R. Butterton3; John Sullivan-Bolyai1 1Idenix Pharmaceuticals Inc., a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; 2Algorithme Pharma, Montreal, Quebec, Canada; 3Merck & Co., Inc., Kenilworth, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif